Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial.

Infection · 2026 · PMC12864199 · PMID 41299123

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

With respect to cellular immunity, while we observed several numeric increases in IFNg release from T-cell-specific peptides (SARS-CoV-2-specific and CRAGs) in the standard-dose group relative to placebo, these changes were not fully congruent with the serologic findings and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.